Commercial Space Company Risk / Opportunity Ranking

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Camphouse after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Capsa AI after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CardNexus after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CeQur after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No reviewed sources-supported positive thesis is available. The reviewed sources explicitly says the summaries do not clearly connect CITIC Group to a qualifying space business.

Why now: There is no current catalyst. Despite 4,475 article IDs considered, the reviewed sources reports zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase2 rationale references article IDs: and: as context, but no were provided in the reviewed sources. Very large raw mention universe does not imply conviction or thesis attractiveness. Possible name/alias ambiguity is unresolved by the reviewed sources.

Thesis: No positive thesis is supported. The reviewed sources rationale says COMSAT appears only in the context of Intuitive Machines acquiring Goonhilly Earth Station/COMSAT, which is indirect and not sufficient for a company-specific opportunity view.

Why now: No 90-day article summaries or evidence were available for COMSAT in these reviewed sources, so there is no supported timing catalyst.

Caveats: Relations/context-only style mention should not be used as counterparty propagation evidence. Phase2 rationale references article ids: and: but no or summaries are provided in the reviewed sources. No direct evidence were available after recent evidence window.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale says EaglePicher is a key player in space batteries and that its systems were on NASA CLPS lunar lander missions, but no retained direct positive evidence or article summaries are available here.

Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set.

Thesis: The reviewed sources only indicates service/testing relevance in a Sidus-related context, and it contains no retained direct positive evidence with inside the recent evidence window, so there is no supported opportunity thesis.

Why now: Why now is absent because only 2 articles were considered and none survived the 90-day filter; there is no current evidence basis for a 1 year+ directional call.

Caveats: Coverage is extremely sparse. The only described relation is context/service oriented and relations are context-only unless policy-gated. No post-cutoff evidence available.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale references IHI benefiting from ICEYE SAR satellites and planning multi-sensor integration, but no retained direct evidence or article summaries are present here.

Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available.

Thesis: No direct positive evidence is available, and the reviewed sources say the included summaries do not clearly establish what Island Green Capital is.

Why now: No timing-based catalyst is supported because no post-recent evidence window evidence were available.

Caveats: Phase2 rationale references article IDs: and: but no were provided in the reviewed sources. Reviewed evidence states summaries were about Molten Ventures and Isar Aerospace rather than clearly about Island Green Capital. Context-only mentions cannot support propagation.

Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window.

Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window.

Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale describes air-launch and testing platform exposure, but no retained direct positive evidence or article summaries are provided here.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count.

Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale notes a letter of intent related to debris removal services, but no direct retained evidence row or article summary is provided in these reviewed sources.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis.

Thesis: No supported positive thesis. The reviewed sources say SWISSto12 is only mentioned in passing in an article about SpaceLocker, which is provisional single-article context and not company-specific evidence, unavailable in reviewed sources).

Why now: There is no identifiable catalyst because the reviewed sources provide only a passing mention and no direct event or fact evidence.

Caveats: No current evidence is provided for. Support level is provisional single-article context only. No evidence available after recent evidence window.

Thesis: No positive thesis is supported. Veact appears only via a broad funding roundup and is not linked to a space-specific category in the reviewed sources.

Why now: No why-now catalyst is supported because the reviewed sources contain no post-recent evidence window evidence.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. A broad funding roundup is not enough to establish thesis direction. Coverage data shows articles after recent evidence window = 0.

Thesis: No direct positive evidence is available. The reviewed sources only says Volteum surfaced from a general funding roundup with no space-specific linkage.

Why now: No catalyst is supported in the reviewed sources due to zero post-recent evidence window evidence.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. Funding-roundup presence alone is not directional proof. Evidence strength remains minimal.

Thesis: No reviewed sources-supported positive thesis is available. Zaro is only listed in a general funding roundup with no direct linkage to a qualifying space thesis.

Why now: There is no current or durable catalyst supported by the reviewed sources because no evidence survived into the available post-recent evidence window set.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. General funding-roundup context is weaker than direct event or fact evidence. Coverage remains insufficient for a directional call.

Thesis: No positive thesis can be supported from the reviewed sources because there is no direct positive evidence available for Zone14 within the 90-day recent evidence window.

Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence.

Thesis: Risk is mainly early-stage execution uncertainty and limited evidence depth: only two articles considered and zero available evidence after recent evidence window.

Why now: Why now is weak because the reviewed sources does not establish current demo timing or funding status with direct evidence after recent evidence window.

Caveats: Private company with thin visible evidence in these reviewed sources. Mission/demo status cannot be validated from available evidence.

Thesis: The main risk is evidentiary: the reviewed sources lack strong recent company-specific event/facts within the recent evidence window, limiting confidence on current execution state.

Why now: Why-now is weak because retained evidence after recent evidence window is mostly undated context; one cited article is from February 14, 2026 and therefore outside the 90-day evidence window, while the remaining available context is undated.

Caveats: Reviewed evidence membership rationale mentions a €119 million ESA contract, but no citeable retained row for that contract is included here. Series D funding mention is in a February 14, 2026 article outside the 90-day recent evidence window. Undated context is not recency proof.

Thesis: The risk is that none of the cited grant or partnership evidence is actually available into the kept post-recent evidence window evidence set, so durability, funding size, execution status, and commercial conversion remain unverified in the reviewed sources.

Why now: The reviewed sources references: and: in the membership rationale, suggesting relatively recent strategic developments, but the coverage report still shows zero evidence after recent evidence window, so timing confidence is limited.

Caveats: Positive thesis relies on membership rationale, not available direct evidence. Partnership evidence cannot be expanded through relation propagation beyond what is explicitly stated.

Thesis: Main risk in these reviewed sources is evidence absence rather than a documented business setback. With no available within the recent evidence window direct positive or negative evidence, visibility into current traction, financing, or execution is poor.

Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, making recency and business-state assessment uncertain.

Caveats: Phase-2 membership rationale references: but no or available evidence row is provided in these reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Cannot treat cohort membership as thesis attractiveness.

Thesis: Risk is mostly normal scale-up and execution risk from pursuing ambitious transportation and recovery-platform goals; the reviewed sources does not provide direct negative evidence such as delays, litigation, or financing stress.

Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon.

Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration.

Thesis: The reviewed sources does not provide material negative evidence, but development and mission-execution risk remain implicit because the thesis rests on a demonstration mission rather than proven commercial scale.

Why now: The membership rationale specifically points to the LOXSAT mission demonstration as the current relevance driver, citing article: but the reviewed sources does not include the article or more detailed dated evidence fields.

Caveats: Underlying article is not provided in the reviewed sources. Score is based on membership rationale summary rather than available direct evidence. Single-mission validation is weaker than broad commercial traction.

Thesis: The evidence is minimal and mostly acquisition context rather than direct company-specific operating evidence. Without retained post-recent evidence window detail, there is no basis for a stronger opportunity or risk call, and ownership/status changes may have already altered standalone operating exposure.

Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence.

Thesis: The main risk is evidentiary uncertainty: there is no available direct adverse evidence, but there is also no post-recent evidence window operating, financing, customer, or execution evidence to confirm momentum.

Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report.

Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence.

Thesis: The evidence is limited to one recent article-level source and does not provide strong company-specific downside evidence, so risk stays low but uncertainty remains high.

Why now: A dated May 26, 2026 article puts a fresh NASA program win into the current evidence window, which can matter over a 1 year+ horizon even if revenue realization is later.

Caveats: Only one within the recent evidence window article is available. Evidence is supporting article context rather than stronger extracted direct events. Timing of mission realization is long-dated relative to the evidence window.

Thesis: Risk is mainly lack of current evidentiary confirmation rather than documented business trouble.

Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence.

Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately.

Thesis: Risk is mainly evidence uncertainty rather than documented adverse developments, because no direct negative evidence or current operating milestones were available after the recent evidence filter.

Why now: There is no within the recent evidence window evidence available for this entity in the reviewed sources; recency of any business progress is uncertain.

Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff for this entity. Membership rationale references article IDs, and: but no article summaries or direct evidence are included in these reviewed sources for citation-level use. Scores are constrained by absence of directional evidence, not by a proven negative business outcome.

Thesis: No material adverse evidence is present, but the evidence is too limited and research-oriented to reduce uncertainty materially.

Why now: The reviewed sources references article: for the research institute setup, yet does not provide the article or direct event details to assess timing or commercial conversion.

Caveats: Only one article is considered and no representative article object is provided. Research institute formation is weaker than product, contract, or financing milestones. Commercial impact timing is unclear.

Thesis: The same evidence creates moderate execution/classification risk: the company may have financing momentum, but the reviewed sources does not establish that it fits the target cohort or that the funding translates into durable business opportunity. No direct adverse event is available.

Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit.

Thesis: Risk is modest because the evidence base is only one undated, supporting article context with no direct company events beyond funding context, making current status and durability uncertain

Why now: For a 1 year+ horizon, funding can matter, but recency is uncertain because the article is explicitly undated and the reviewed sources say undated external evidence is relevance context rather than recency proof

Caveats: The evidence is weak context and supporting article context, not direct structured company event/fact evidence. The article is undated; the reviewed sources explicitly says recency-sensitive claims should be treated cautiously. Same-article repeated rows are not independent confirmation.

Thesis: The main risk is evidentiary rather than operational: the reviewed sources contain no direct negative evidence, but also no company-specific contract value, backlog, execution milestone, or follow-on detail. The Andromeda item is supporting article context and same-article repeats are not independent confirmation, so the opportunity could be overstated if General Atomics' role is small or non-recurring., April 8, 2026

Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026

Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation.

Thesis: The main risk is lack of current standalone visibility: because evidence appears tied to acquired-business context and no retained rows are included, current operating status, ownership implications, and commercial significance cannot be established from these reviewed sources.

Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank.

Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business.

Thesis: Risk appears limited based on the reviewed sources only because there is no adverse evidence, but confidence is low since there is also no direct traction, contract, funding, or milestone evidence available.

Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view.

Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence.

Thesis: There is no direct adverse evidence in the reviewed sources; risk is limited to uncertainty from missing current evidence rather than any documented deterioration.

Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk.

Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence.

Thesis: No direct negative evidence is shown; key risk is uncertainty around monetization, expansion beyond Phase I, and lack of corroborating direct evidence in the reviewed sources.

Why now: The why-now would be the reported trial license and completed Phase I constellation, but the reviewed sources does not provide the underlying article summary or date-specific evidence for stronger timing confidence.

Caveats: Phase2 membership rationale references: but no summary/evidence row is available to cite directly. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Score exceeds Beijing Guodian High-Tech slightly because rationale mentions both licensing and constellation completion.

Thesis: The reviewed sources also says the company-specific operating category is not clearly established from the provided evidence alone. That uncertainty, plus the lack of retained direct evidence, limits confidence in any positive thesis.

Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact.